Important: Rodent colitis data used oral or nanoparticle delivery; no human efficacy, safety or pharmacokinetic data for KPV exist. The 2026 FDA advisory vote concerns compounding eligibility only.
Overview
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH residues 11–13). It retains the anti-inflammatory activity of the parent hormone while lacking the pigmentary (MC1R-driven melanogenic) effects, which is why it was isolated as a research tool in the 1990s. The best-characterised work is in intestinal inflammation: KPV is transported into intestinal epithelial and immune cells by the oligopeptide transporter PepT1, where it suppresses NF-κB activation and pro-inflammatory cytokine output, and oral KPV reduced colitis severity in DSS and TNBS mouse models.
Interest in KPV rose in 2026 when an FDA advisory panel voted to recommend it for the 503A bulk-substances list for compounding — a regulatory signal, not a proof of efficacy. All efficacy data remain preclinical; there are no controlled human trials of KPV as a therapeutic.
Mechanism of Action
KPV exerts anti-inflammatory effects through at least two routes. First, unlike full-length α-MSH it does not require melanocortin receptor signalling for much of its effect: after PepT1-mediated uptake into epithelial and immune cells, KPV inhibits NF-κB nuclear translocation and downstream transcription of TNF-α, IL-6, IL-8 and IL-1β. Second, KPV can interact directly with the IL-1β signalling axis, which was the basis of the original antipyretic and anti-inflammatory patents.
In colitis models, oral KPV reduced weight loss, colonic shortening, histological damage and MPO activity, and lowered pro-inflammatory cytokine expression; the effect was lost in PepT1-deficient conditions, tying the mechanism to transporter-mediated uptake. KPV also reduced inflammatory signalling in keratinocytes and models of dermal inflammation, consistent with the broad anti-inflammatory profile of the melanocortin C-terminus.
Research Evidence
- Oral KPV reduced DSS- and TNBS-induced colitis in mice, with lower pro-inflammatory cytokine expression; uptake occurred via PepT1 on intestinal epithelial and immune cells (Dalmasso et al., Gastroenterology 2008; PMID 18061177)
- KPV ameliorated disease in murine IBD models and inhibited NF-κB activation in intestinal epithelial cells and T cells (Kannengiesser et al., Inflamm Bowel Dis 2008; PMID 18092346)
- KPV retains α-MSH's anti-inflammatory and antipyretic activity without melanogenic (pigmentary) effects — the reason the tripeptide was isolated (Brzoska et al., Endocrine Reviews 2008)
- Hyaluronic-acid-functionalised nanoparticles loaded with KPV alleviated ulcerative colitis in mice at ~12,000-fold lower dose than free KPV in drinking water (Xiao et al., Molecular Therapy 2017)
- On 23–24 July 2026 an FDA advisory panel voted 8–6 to recommend KPV for the 503A bulk-substances list for compounding — a regulatory step, not a demonstration of clinical efficacy
Bottom line: All efficacy evidence is in mice and cells. There are no controlled human trials. The FDA panel vote is a regulatory step about compounding eligibility, not proof it works in people. Research-only.
Evidence & References
The full compound profile lists the evidence level, the studies behind each claim with PubMed links, and the adverse-effect record. Compound Review does not publish dosing protocols.
Sourcing & Quality
KPV is available from Purgo Labs with third-party COA verification and research-grade purity standards. View KPV at Purgo Labs.